Riboflavin topical - Avedro
Alternative Names: Epi-on; Epioxa; Epioxa HD; Epioxa™; iLink™; KXL; KXL System®; ParaCel; Paracel 1; Paracel 2 R0185; Photrexa; Photrexa Viscous; Riboflavin 5’-phosphate in 20% dextran ophthalmic solution; Riboflavin 5’-phosphate ophthalmic solution; Riboflavin ophthalmic solution; Riboflavin ophthalmic solution/KXL system; VibeX; VibeX Rapid; VibeX XtraLatest Information Update: 28 Oct 2025
At a glance
- Originator Avedro
- Class Antimigraines; Eye disorder therapies; Flavins; Small molecules; Vitamins
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Yes - Corneal injuries; Keratoconus
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Corneal injuries; Keratoconus
Most Recent Events
- 20 Oct 2025 Registered for Keratoconus (In adolescents, In adults) in USA (Ophthalmic, Solution)
- 20 Oct 2025 Glaukos plans to launch Epioxa for Keratoconus (In adolescents, In adults) in USA (Ophthalmic, Solution) in the first quarter of 2026
- 24 Feb 2025 US FDA assigns PDUFA action date of (20/10/2025) for Riboflavin topical for Keratoconus